Rational Design of Vaccines. Learning from Immune Evasion Mechanisms of Persistent Viruses and Tumors.

Advances in Immunology

Volumn 114, Issue , 2012, Pages 217-243

  Arens, Ramon ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Costimulation; Cytokine; DNA viruses; IFN; Immune evasion mechanism; T cells; Vaccine

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; CYTOMEGALOVIRUS VECTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; HISTONE DEACETYLASE INHIBITOR; INTERFERON; INTERLEUKIN 10 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CONDYLOMA ACUMINATUM; DNA VIRUS; DRUG DESIGN; HEPATITIS B; HEPATITIS C; HERPES VIRUS; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION CONTROL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR ESCAPE; TUMOR IMMUNOLOGY; VACCINATION; VIRUS; VIRUS IMMUNITY;

EID: 84858774207     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396548-6.00009-3     Document Type: Chapter

References (167)

1. Agaugue S., Carosella E.D., Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011, 117:7021-7031.
2. Alcami A., Symons J.A., Collins P.D., Williams T.J., Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 1998, 160:624-633.
3. Alimonti J., Zhang Q.J., Gabathuler R., Reid G., Chen S.S., Jefferies W.A. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 2000, 18:515-520.
4. Alzhanova D., Edwards D.M., Hammarlund E., Scholz I.G., Horst D., Wagner M.J., Upton C., Wiertz E.J., Slifka M.K., Fruh K. Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe 2009, 6:433-445.
5. Andrews D.M., Andoniou C.E., Granucci F., Ricciardi-Castagnoli P., Degli-Esposti M.A. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat. Immunol. 2001, 2:1077-1084.
6. Arav-Boger R., Willoughby R.E., Pass R.F., Zong J.C., Jang W.J., Alcendor D., Hayward G.S. Polymorphisms of the cytomegalovirus (CMV)-encoded tumor necrosis factor-alpha and beta-chemokine receptors in congenital CMV disease. J. Infect. Dis. 2002, 186:1057-1064.
7. Arens R., Loewendorf A., Her M.J., Schneider-Ohrum K., Shellam G.R., Janssen E., Ware C.F., Schoenberger S.P., Benedict C.A. B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J. Virol. 2011, 85:390-396.
8. Beisser P.S., Vink C., van Dam J.G., Grauls G., Vanherle S.J., Bruggeman C.A. The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection. J. Virol. 1998, 72:2352-2363.
9. Beisser P.S., Verzijl D., Gruijthuijsen Y.K., Beuken E., Smit M.J., Leurs R., Bruggeman C.A., Vink C. The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol. 2005, 79:441-449.
10. Benedict C.A., Butrovich K.D., Lurain N.S., Corbeil J., Rooney I., Schneider P., Tschopp J., Ware C.F. Cutting edge: A novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 1999, 162:6967-6970.
11. Benedict C.A., Loewendorf A., Garcia Z., Blazar B.R., Janssen E.M. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J. Immunol. 2008, 180:4836-4847.
12. Billard C., Sigaux F., Castaigne S., Valensi F., Flandrin G., Degos L., Falcoff E., Aguet M. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 1986, 67:821-826.
13. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000, 342:1350-1358.
14. Boname J.M., de Lima B.D., Lehner P.J., Stevenson P.G. Viral degradation of the MHC class I peptide loading complex. Immunity 2004, 20:305-317.
15. Bongers G., Maussang D., Muniz L.R., Noriega V.M., Fraile-Ramos A., Barker N., Marchesi F., Thirunarayanan N., Vischer H.F., Qin L., Mayer L., Harpaz N., et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J. Clin. Invest. 2010, 120:3969-3978.
16. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24:175-208.
17. Brownstein D.G., Bhatt P.N., Gras L., Jacoby R.O. Chromosomal locations and gonadal dependence of genes that mediate resistance to ectromelia (mousepox) virus-induced mortality. J. Virol. 1991, 65:1946-1951.
18. Budt M., Niederstadt L., Valchanova R.S., Jonjic S., Brune W. Specific inhibition of the PKR-mediated antiviral response by the murine cytomegalovirus proteins m142 and m143. J. Virol. 2009, 83:1260-1270.
19. Byun M., Verweij M.C., Pickup D.J., Wiertz E.J., Hansen T.H., Yokoyama W.M. Two mechanistically distinct immune evasion proteins of cowpox virus combine to avoid antiviral CD8 T cells. Cell Host Microbe 2009, 6:422-432.
20. Campoli M., Ferrone S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 2008, 27:5869-5885.
21. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 2010, 20:202-213.
22. Carretero R., Romero J.M., Ruiz-Cabello F., Maleno I., Rodriguez F., Camacho F.M., Real L.M., Garrido F., Cabrera T. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008, 60:439-447.
23. Chappert P., Schwartz R.H. Induction of T cell anergy: Integration of environmental cues and infectious tolerance. Curr. Opin. Immunol. 2010, 22:552-559.
24. Child S.J., Geballe A.P. Binding and relocalization of protein kinase R by murine cytomegalovirus. J. Virol. 2009, 83:1790-1799.
25. Child S.J., Hakki M., De Niro K.L., Geballe A.P. Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J. Virol. 2004, 78:197-205.
26. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004, 14:149-154.
27. Croft M. Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity?. Nat. Rev. Immunol. 2003, 3:609-620.
28. Davis-Poynter N.J., Lynch D.M., Vally H., Shellam G.R., Rawlinson W.D., Barrell B.G., Farrell H.E. Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J. Virol. 1997, 71:1521-1529.
29. de Waal M.R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
30. Defilippis V.R. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv. Exp. Med. Biol. 2007, 598:309-324.
31. Donkor M.K., Sarkar A., Savage P.A., Franklin R.A., Johnson L.K., Jungbluth A.A., Allison J.P., Li M.O. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011, 35:123-134.
32. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
33. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
34. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
35. Fleming P., Davis-Poynter N., Degli-Esposti M., Densley E., Papadimitriou J., Shellam G., Farrell H. The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity. J. Virol. 1999, 73:6800-6809.
36. French R.R., Chan H.T., Tutt A.L., Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999, 5:548-553.
37. French A.R., Pingel J.T., Wagner M., Bubic I., Yang L., Kim S., Koszinowski U., Jonjic S., Yokoyama W.M. Escape of mutant double-stranded DNA virus from innate immune control. Immunity 2004, 20:747-756.
38. French R.R., Taraban V.Y., Crowther G.R., Rowley T.F., Gray J.C., Johnson P.W., Tutt A.L., Al-Shamkhani A., Glennie M.J. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007, 109:4810-4815.
39. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
40. Garrido F., Cabrera T., Aptsiauri N. " Hard" and " soft" lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int. J. Cancer 2010, 127:249-256.
41. Gold M.C., Munks M.W., Wagner M., McMahon C.W., Kelly A., Kavanagh D.G., Slifka M.K., Koszinowski U.H., Raulet D.H., Hill A.B. Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J. Immunol. 2004, 172:6944-6953.
42. Gray J.C., French R.R., James S., Al-Shamkhani A., Johnson P.W., Glennie M.J. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 2008, 38:2499-2511.
43. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
44. Grey F., Hook L., Nelson J. The functions of herpesvirus-encoded microRNAs. Med. Microbiol. Immunol. 2008, 197:261-267.
45. Hansen T.H., Bouvier M. MHC class I antigen presentation: Learning from viral evasion strategies. Nat. Rev. Immunol. 2009, 9:503-513.
46. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
47. Hansen S.G., Powers C.J., Richards R., Ventura A.B., Ford J.C., Siess D., Axthelm M.K., Nelson J.A., Jarvis M.A., Picker L.J., Fruh K. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010, 328:102-106.
48. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
49. Heath W.R., Carbone F.R. Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol. 2001, 1:126-134.
50. Hegde N.R., Tomazin R.A., Wisner T.W., Dunn C., Boname J.M., Lewinsohn D.M., Johnson D.C. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: A novel mechanism for evading major histocompatibility complex class II antigen presentation. J. Virol. 2002, 76:10929-10941.
51. Hegde N.R., Chevalier M.S., Johnson D.C. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 2003, 24:278-285.
52. Hislop A.D., Ressing M.E., van Leeuwen D., Pudney V.A., Horst D., Koppers-Lalic D., Croft N.P., Neefjes J.J., Rickinson A.B., Wiertz E.J. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 2007, 204:1863-1873.
53. Huh Y.H., Kim Y.E., Kim E.T., Park J.J., Song M.J., Zhu H., Hayward G.S., Ahn J.H. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 2008, 82:10444-10454.
54. Iempridee T., Das S., Xu I., Mertz J.E. Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene. J. Virol. 2011, 85:7836-7848.
55. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:258-267.
56. Ishida T., Ueda R. Immunopathogenesis of lymphoma: Focus on CCR4. Cancer Sci. 2011, 102:44-50.
57. Jensen S.M., Maston L.D., Gough M.J., Ruby C.E., Redmond W.L., Crittenden M., Li Y., Puri S., Poehlein C.H., Morris N., Kovacsovics-Bankowski M., Moudgil T., et al. Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 2010, 37:524-532.
58. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 2010, 59:1707-1714.
59. Jin H.T., Ahmed R., Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 2011, 350:17-37.
60. Johnson D.C., Hegde N.R. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Curr. Top. Microbiol. Immunol. 2002, 269:101-115.
61. Kaptein S.J., Beisser P.S., Gruijthuijsen Y.K., Savelkouls K.G., van Cleef K.W., Beuken E., Grauls G.E., Bruggeman C.A., Vink C. The rat cytomegalovirus R78 G protein-coupled receptor gene is required for production of infectious virus in the spleen. J. Gen. Virol. 2003, 84:2517-2530.
62. Karre K. Natural killer cell recognition of missing self. Nat. Immunol. 2008, 9:477-480.
63. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 2009, 182:5891-5897.
64. Khalil M., Vonderheide R.H. Anti-CD40 agonist antibodies: Preclinical and clinical experience. Update Cancer Ther. 2007, 2:61-65.
65. Khan A.N., Tomasi T.B. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol. Res. 2008, 40:164-178.
66. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of " tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
67. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 2010, 22:223-230.
68. Kim S., Lee S., Shin J., Kim Y., Evnouchidou I., Kim D., Kim Y.K., Kim Y.E., Ahn J.H., Riddell S.R., Stratikos E., Kim V.N., et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat. Immunol. 2011, 12:984-991.
69. Kledal T.N., Rosenkilde M.M., Schwartz T.W. Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett. 1998, 441:209-214.
70. Komyod W., Bohm M., Metze D., Heinrich P.C., Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol. Cancer Res. 2007, 5:271-281.
71. Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006, 90:297-339.
72. Korpal M., Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur. J. Cancer 2010, 46:1232-1240.
73. Kotenko S.V., Saccani S., Izotova L.S., Mirochnitchenko O.V., Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA 2000, 97:1695-1700.
74. Krauss S., Kaps J., Czech N., Paulus C., Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 2009, 83:12854-12870.
75. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203:871-881.
76. Kryczek I., Wei S., Zhu G., Myers L., Mottram P., Cheng P., Chen L., Coukos G., Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007, 67:8900-8905.
77. Kuhn D.E., Beall C.J., Kolattukudy P.E. The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem. Biophys. Res. Commun. 1995, 211:325-330.
78. Kwak H., Horig H., Kaufman H.L. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Devel. 2003, 6:161-168.
79. Lampen M.H., van Hall T. Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 2011, 23:293-298.
80. Lautscham G., Rickinson A., Blake N. TAP-independent antigen presentation on MHC class I molecules: Lessons from Epstein-Barr virus. Microbes Infect. 2003, 5:291-299.
81. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., Roederer M., Davis M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5:677-685.
82. Lee B.J., Koszinowski U.H., Sarawar S.R., Adler H. A gammaherpesvirus G protein-coupled receptor homologue is required for increased viral replication in response to chemokines and efficient reactivation from latency. J. Immunol. 2003, 170:243-251.
83. Lee H., Pal S.K., Reckamp K., Figlin R.A., Yu H. STAT3: A target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 2011, 344:41-59.
84. Lefkowitz E.J., Wang C., Upton C. Poxviruses: Past, present and future. Virus Res. 2006, 117:105-118.
85. Li M.O., Flavell R.A. TGF-beta: A master of all T cell trades. Cell 2008, 134:392-404.
86. Li P., Wang N., Zhou D., Yee C.S., Chang C.H., Brutkiewicz R.R., Blum J.S. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 2005, 175:6481-6488.
87. Liang C.L., Chen J.L., Hsu Y.P., Ou J.T., Chang Y.S. Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins. J. Biol. Chem. 2002, 277:23345-23357.
88. Loewendorf A., Kruger C., Borst E.M., Wagner M., Just U., Messerle M. Identification of a mouse cytomegalovirus gene selectively targeting CD86 expression on antigen-presenting cells. J. Virol. 2004, 78:13062-13071.
89. Loewendorf A.I., Steinbrueck L., Peter C., Busche A., Benedict C.A., Kay-Jackson P.C. The mouse cytomegalovirus glycoprotein m155 inhibits CD40 expression and restricts CD4 T cell responses. J. Virol. 2011, 85:5208-5212.
90. Luttichau H.R. The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist. J. Biol. Chem. 2010, 285:9137-9146.
91. Lybarger L., Wang X., Harris M.R., Virgin H.W., Hansen T.H. Virus subversion of the MHC class I peptide-loading complex. Immunity 2003, 18:121-130.
92. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
93. Maussang D., Vischer H.F., Leurs R., Smit M.J. Herpesvirus-encoded G protein-coupled receptors as modulators of cellular function. Mol. Pharmacol. 2009, 76:692-701.
94. McGeoch D.J., Cook S., Dolan A., Jamieson F.E., Telford E.A. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J. Mol. Biol. 1995, 247:443-458.
95. Mestas J., Burdick M.D., Reckamp K., Pantuck A., Figlin R.A., Strieter R.M. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 2005, 175:5351-5357.
96. Meulmeester E., Ten Dijke P. The dynamic roles of TGF-beta in cancer. J. Pathol. 2011, 223:205-218.
97. Michaelis M., Doerr H.W., Cinatl J. The story of human cytomegalovirus and cancer: Increasing evidence and open questions. Neoplasia 2009, 11:1-9.
98. Michelson S., Alcami J., Kim S.J., Danielpour D., Bachelerie F., Picard L., Bessia C., Paya C., Virelizier J.L. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J. Virol. 1994, 68:5730-5737.
99. Mintern J.D., Klemm E.J., Wagner M., Paquet M.E., Napier M.D., Kim Y.M., Koszinowski U.H., Ploegh H.L. Viral interference with B7-1 costimulation: A new role for murine cytomegalovirus fc receptor-1. J. Immunol. 2006, 177:8422-8431.
100. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990, 248:1230-1234.
101. Moorman N.J., Virgin H.W., Speck S.H. Disruption of the gene encoding the gammaHV68 v-GPCR leads to decreased efficiency of reactivation from latency. Virology 2003, 307:179-190.
102. Moutaftsi M., Mehl A.M., Borysiewicz L.K., Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002, 99:2913-2921.
103. Munks M.W., Pinto A.K., Doom C.M., Hill A.B. Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J. Immunol. 2007, 178:7235-7241.
104. Nakayama T., Hieshima K., Nagakubo D., Sato E., Nakayama M., Kawa K., Yoshie O. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 2004, 78:1665-1674.
105. Nijmeijer S., Leurs R., Smit M.J., Vischer H.F. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Galphai proteins, and constitutively impairs CXCR4 functioning. J. Biol. Chem. 2010, 285:29632-29641.
106. O'Connor C.M., Shenk T. Human cytomegalovirus pUS27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell-to-cell spread. J. Virol. 2011, 85:3700-3707.
107. Oliveira S.A., Shenk T.E. Murine cytomegalovirus M78 protein, a G protein-coupled receptor homologue, is a constituent of the virion and facilitates accumulation of immediate-early viral mRNA. Proc. Natl. Acad. Sci. USA 2001, 98:3237-3242.
108. Parry C.M., Simas J.P., Smith V.P., Stewart C.A., Minson A.C., Efstathiou S., Alcami A. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 2000, 191:573-578.
109. Paulsen S.J., Rosenkilde M.M., Eugen-Olsen J., Kledal T.N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 2005, 79:536-546.
110. Paulus C., Krauss S., Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA 2006, 103:3840-3845.
111. Penfold M.E., Dairaghi D.J., Duke G.M., Saederup N., Mocarski E.S., Kemble G.W., Schall T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA 1999, 96:9839-9844.
112. Ploegh H.L. Viral strategies of immune evasion. Science 1998, 280:248-253.
113. Quandt D., Fiedler E., Boettcher D., Marsch W.C., Seliger B. B7-h4 expression in human melanoma: Its association with patients' survival and antitumor immune response. Clin. Cancer Res. 2011, 17:3100-3111.
114. Ranheim E.A., Cantwell M.J., Kipps T.J. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995, 85:3556-3565.
115. Rappuoli R., Miller H.I., Falkow S. Medicine. The intangible value of vaccination. Science 2002, 297:937-939.
116. Rappuoli R., Black S., Lambert P.H. Vaccine discovery and translation of new vaccine technology. Lancet 2011, 378:360-368.
117. Rehm K.E., Connor R.F., Jones G.J., Yimbu K., Roper R.L. Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 2010, 397:176-186.
118. Ressing M.E., van Leeuwen D., Verreck F.A., Keating S., Gomez R., Franken K.L., Ottenhoff T.H., Spriggs M., Schumacher T.N., Hutt-Fletcher L.M., Rowe M., Wiertz E.J. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J. Virol. 2005, 79:841-852.
119. Rodriguez T., Mendez R., Del C.A., Jimenez P., Aptsiauri N., Garrido F., Ruiz-Cabello F. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 2007, 7:34.
120. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298:2155-2163.
121. Sabat R., Grutz G., Warszawska K., Kirsch S., Witte E., Wolk K., Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010, 21:331-344.
122. Salek-Ardakani S., Arrand J.R., Mackett M. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: Implications for immune evasion by EBV. Virology 2002, 304:342-351.
123. Savage P.A., Vosseller K., Kang C., Larimore K., Riedel E., Wojnoonski K., Jungbluth A.A., Allison J.P. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008, 319:215-220.
124. Schietinger A., Philip M., Schreiber H. Specificity in cancer immunotherapy. Semin. Immunol. 2008, 20:276-285.
125. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
126. Seet B.T., McFadden G. Viral chemokine-binding proteins. J. Leukoc. Biol. 2002, 72:24-34.
127. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 2008, 57:1719-1726.
128. Seliger B., Marincola F.M., Ferrone S., Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol. Med. 2008, 14:550-559.
129. Seliger B., Ruiz-Cabello F., Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv. Cancer Res. 2008, 101:249-276.
130. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 2001, 55:255-281.
131. Seo J.Y., Yaneva R., Hinson E.R., Cresswell P. Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity. Science 2011, 332:1093-1097.
132. Setiadi A.F., Omilusik K., David M.D., Seipp R.P., Hartikainen J., Gopaul R., Choi K.B., Jefferies W.A. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008, 68:9601-9607.
133. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
134. Singh S., Singh A.P., Sharma B., Owen L.B., Singh R.K. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol. 2010, 6:111-116.
135. Smith G.L., Symons J.A., Khanna A., Vanderplasschen A., Alcami A. Vaccinia virus immune evasion. Immunol. Rev. 1997, 159:137-154.
136. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J. Intern. Med. 2006, 259:219-246.
137. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267:271-285.
138. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
139. Stevenson P.G., May J.S., Smith X.G., Marques S., Adler H., Koszinowski U.H., Simas J.P., Efstathiou S. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat. Immunol. 2002, 3:733-740.
140. Symons J.A., Alcami A., Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995, 81:551-560.
141. Takegawa S., Jin Z., Nakayama T., Oyama T., Hieshima K., Nagakubo D., Shirakawa A.K., Tsuzuki T., Nakamura S., Yoshie O. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci. 2008, 99:296-302.
142. Taylor R.T., Bresnahan W.A. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J. Virol. 2005, 79:3873-3877.
143. Taylor R.T., Bresnahan W.A. Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression. J. Virol. 2006, 80:920-928.
144. Thomas G.R., Wen J. Endogenous expression of CD80 co-stimulatory molecule facilitates in vivo tumor regression of oral squamous carcinoma. Anticancer Res. 2006, 26:4093-4101.
145. Tomazin R., Boname J., Hegde N.R., Lewinsohn D.M., Altschuler Y., Jones T.R., Cresswell P., Nelson J.A., Riddell S.R., Johnson D.C. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat. Med. 1999, 5:1039-1043.
146. Valchanova R.S., Picard-Maureau M., Budt M., Brune W. Murine cytomegalovirus m142 and m143 are both required to block protein kinase R-mediated shutdown of protein synthesis. J. Virol. 2006, 80:10181-10190.
147. van Berkel V., Barrett J., Tiffany H.L., Fremont D.H., Murphy P.M., McFadden G., Speck S.H., Virgin H.W. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 2000, 74:6741-6747.
148. van Berkel V., Levine B., Kapadia S.B., Goldman J.E., Speck S.H., Virgin H.W. Critical role for a high-affinity chemokine-binding protein in gamma-herpesvirus-induced lethal meningitis. J. Clin. Invest. 2002, 109:905-914.
149. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., Meiring H., de Jong A., Franken K., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 2006, 12:417-424.
150. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
151. van Oers M.H., Pals S.T., Evers L.M., van der Schoot C.E., Koopman G., Bonfrer J.M., Hintzen R.Q., von dem Borne A.E., van Lier R.A. Expression and release of CD27 in human B-cell malignancies. Blood 1993, 82:3430-3436.
152. Vieira P., de Waal-Malefyt R., Dang M.N., Johnson K.E., Kastelein R., Fiorentino D.F., deVries J.E., Roncarolo M.G., Mosmann T.R., Moore K.W. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. USA 1991, 88:1172-1176.
153. Voigt V., Forbes C.A., Tonkin J.N., Degli-Esposti M.A., Smith H.R., Yokoyama W.M., Scalzo A.A. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc. Natl. Acad. Sci. USA 2003, 100:13483-13488.
154. Wang D., Bresnahan W., Shenk T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc. Natl. Acad. Sci. USA 2004, 101:16642-16647.
155. Waters A., Hassan J., De G.C., Kissoon G., Knowles S., Molloy E., Connell J., Hall W.W. Human cytomegalovirus UL144 is associated with viremia and infant development sequelae in congenital infection. J. Clin. Microbiol. 2010, 48:3956-3962.
156. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005, 23:23-68.
157. Wilke C.M., Wei S., Wang L., Kryczek I., Kao J., Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol. Immunother. 2011, 60:1529-1541.
158. Willimsky G., Blankenstein T. The adaptive immune response to sporadic cancer. Immunol. Rev. 2007, 220:102-112.
159. Wilson E.B., Brooks D.G. The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 2011, 350:39-65.
160. Wischhusen J., Jung G., Radovanovic I., Beier C., Steinbach J.P., Rimner A., Huang H., Schulz J.B., Ohgaki H., Aguzzi A., Rammensee H.G., Weller M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 2002, 62:2592-2599.
161. Xi S., Dyer K.F., Kimak M., Zhang Q., Gooding W.E., Chaillet J.R., Chai R.L., Ferrell R.E., Zamboni B., Hunt J., Grandis J.R. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J. Natl. Cancer Inst. 2006, 98:181-189.
162. Yewdell J.W., Hill A.B. Viral interference with antigen presentation. Nat. Immunol. 2002, 3:1019-1025.
163. Yu S.E., Park S.H., Jang Y.K. Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol. Cells 2010, 29:217-221.
164. Zimmermann A., Trilling M., Wagner M., Wilborn M., Bubic I., Jonjic S., Koszinowski U., Hengel H. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J. Exp. Med. 2005, 201:1543-1553.
165. Zlotnik A., Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000, 12:121-127.
166. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8:467-477.
167. Zuo J., Currin A., Griffin B.D., Shannon-Lowe C., Thomas W.A., Ressing M.E., Wiertz E.J., Rowe M. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009, 5:e1000255.